MUMBAI, India, Sept. 14 -- Intellectual Property India has published a patent application (202617064711 A) filed by B Pharmaceuticals on May 22, 2026, for P-Cadherin Ligands.
Inventors include Al-Obaidi, Naowras; Osterkamp, Frank; Schneider, Eberhard; Hhne, Aileen; Zboralski, Dirk; Wahsner-Teschner, Jessica; Smerling, Christiane; Reineke, Ulrich; Drger, Carolin; Nikolaeva, Olga; and Reimer, Ulf.
The application for the patent was published on September 11, 2026, under issue no. 37/2026.
Abstract: The present invention is related to a P-cadherin binding compound; a composition comprising the P-cadherin binding compound; the P-cadherin binding compound and the composition, respectively, for use in a method for the diagnosis of a disease; the P-cadherin binding compound and the composition, respectively, for use in a method for the treatment of a disease; the P-cadherin binding compound and the composition, respectively, for use in a method of diagnosis and treatment of a disease which is also referred to as "thera(g)nosis" or "thera(g)nostics"; the P-cadherin binding compound and the composition, respectively, for use in a method for delivering a radionuclide to a P-cadherin expressing tissue; a method for the diagnosis of a disease using the P-cadherin binding compound and the composition, respectively; a method for the treatment of a disease using the P-cadherin binding compound and the composition, respectively; a method for the diagnosis and treatment of a disease which is also referred to as "thera(g)nosis" or "thera(g)nostics, using the P-cadherin binding compound and the composition, respectively; a method for the delivery of a radionuclide to a P-cadherin expressing tissue using the P-cadherin binding compound and the composition, respectively.
Disclaimer: Curated by HT Syndication.
